Anti-tumor effects of brucine immuno-nanoparticles on hepatocellular carcinoma

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 369-379

  Qin, Jian Min ^a   Yin, Pei Hao ^a   Li, Qi ^a   Sa, Zhong Qiu ^a   Sheng, Xia ^a   Yang, Lin ^a   Huang, Tao ^a   Zhang, Min ^a   Gao, Ke Pan ^b   Chen, Qing Hua ^b   Ma, Jing Wei ^c   Shen, He Bai ^c  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b National Pharmaceutical Engineering Research Center   (China)

^c SHANGHAI NORMAL UNIVERSITY   (China)

Author keywords

Anti tumor effect; Cancer targeting; Hepatocellular carcinoma; Nanoparticles; Targeted drug delivery

Indexed keywords

ALPHA FETOPROTEIN ANTIBODY; BRUCINE; FLUOROURACIL; MACROGOL; NANOPARTICLE; POLYLACTIC ACID; ANTINEOPLASTIC AGENT; BRUCINE ALPHA FETOPROTEIN MONOCLONAL ANTIBODY MACROGOL POLYLACTIC ACID; BRUCINE IMMUNONANOPARTICLE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL MEMBRANE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RELEASE; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; METASTASIS INHIBITION; NANOENCAPSULATION; PARTICLE SIZE; POLYMERIZATION; ZETA POTENTIAL; CANCER INHIBITION; DRUG DELIVERY SYSTEM; PHACOEMULSIFICATION; SLOW DRUG RELEASE; TARGET CELL DESTRUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; IMMUNOTOXINS; LIVER NEOPLASMS; NANOPARTICLES; PARTICLE SIZE; STRYCHNINE;

EID: 84863032578     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S27226     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Tang ZY, Ye SL, Liu YK, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(4): 187-196.
3. Mitsunobu M, Toyosaka A, Oriyama T, Okamoto E, Nakao N. Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel. Clin Exp Metastasis. 1996;14(6): 520-529.
4. Wu MC, Chen H, Zhang XH, Yao X P, Yang JM. Surgical treatment of primary liver cancer: 1102 cases. Acad J Sec Mil Med Univ. 1993; 14(3):201-204.
5. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191(1): 38-46.
6. Ziser A, Plevak DJ, Weisner RH, Rakela J, Offord K P, Brown DL. Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology. 1999;90(1):42-53.
7. Calne R, Yamanoi A, Oura S, Kawamura M. Liver transplantation for hepatocarcinoma. Surg Today. 1993;23(1):1-3.
8. Tang Z Y. The meaning and approach to carry out liver metastasis and recurrence research. Chin J Gen Surg. 2006;21(11):761.
9. Thomas MB, Zhu AX. Hepatocellular carcinoma: The need for progress. J Clin Oncol. 2005;23(13):2892-2899.
10. Wu MC. Surgical treatment of primary liver cancer. Chin J Gen Surg. 2009;3(4):1-3.
11. Qin JM, Xu XJ, Sheng X, et al. The effect of brucine on hepatocellular carcinoma cell lines in vitro. Chin J Gen Surg. 2011;26(3):219-221.
12. Deng XK, Cai BC, Lv X Y, et al. Anti-tumor effects comparision of the brucine and its liposomes in transplanted tumor-bearing mice. J Herb Med. 2006;37(3):389-393.
13. Deng XK, Cai BC, Yin W, Zhang XC, Li WD, Sun Q. Brucine on mouse tumor inhibition. Chin J Nat Med. 2005;3(6):392-396.
14. Deng XK, Cai BC, Yin W, Liu TS, Sun Q, Li WD. Research of the anti-tumor effect and toxicity of brucine in Heps tumor-bearing mice. Chin Pharmacol Bulletin. 2006;22(1):35-39.
15. Qin JM, Zhang YD, Wang HY, Wu MC. Nanotechnologies in the diagnosis and treatment of liver disease. Chin J Hepatobiliary Surg. 2004;10(9):646-648.
16. Wang Y, Li Q, Feng N P, et al. Tanshinone IIA nanoparticles in the treatment of mouse liver cancer and its effects on Cyclin E expression. Shanghai Traditional Chin Med. 2007;4(1):74-77.
17. Torchilin V P. Drug targeting. Eur J Pharm Sci. 2000;11(Suppl 2): S81-S91.
18. Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm. 2002;233(1-2):51-59.
19. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyla-lcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002;82(1):105-114.
20. Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly (D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res. 2003;20(2):212-220.
21. Lynch I. Are there generic mechanisms governing interactions between nanoparticles and cells? Epitope mapping the other layer of the protein- material interface. Physica A. 2007;373(3):511-520.
22. Rowland RES, Taylor P W, Florence AT. Attachment, uptake and transport of nanoparticles coated with an internal in A fragment in Caco-2 cell monolayer. J Drug Deliv Sci Technol. 2005;15(3): 313-317.
23. Wu J, Nantz MH, Zern MA. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Frontiers in Bioscience. 2002;7(1):717-725.
24. Liu XB, Cai MY. Preparation and immunological identifcation of nanoparticles against human hepatocellular carcinoma in vitro. Chin J Immunology. 2000;16(5):262-265.
25. Chen Y, Tang R, Huang W. Study of hepatoma-specifc immunal phospholipids doxorubicin nanoparticles. Chin Pharmacist. 2002; 5(12):712-714.
26. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical signifcance of elevated alpha fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004;99(5):860-865.
27. Montaser LM, Abbas OM, Saltah AM, Waked IA. Circulating AFP mRNA as a possible indicator of hematogenous spread of HCC cells: a possible association with HBV infection. J Egypt Natl Canc Inst. 2007;19(1):48-60.
28. Kamiyama T, Takahashi M, Nakagawa T, et al. AFP mRNA detected in bone marrow by real-time quantitative RT-PCR analysis predicts survival and recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg. 2006;244(3):451-463.
29. van der Heiden PL, Jedema I, Willemze R, Barge RM. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Eur J Haematol. 2006;76(5):409-4l3.
30. Adams G P, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147-1157.
31. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137-1146.
32. Jha RK, Ma Q, Chen S, Sha H, Ding S. Relationship of fbronectin and CD44v6 expression with invasive growth and metastasis of liver cancer. Cancer Invest. 2009;27(3):324-328.
33. Sun H, Liu GT. Inhibitory effect of anti-hepatitis drug bicyclol on invasion of human hepatocellular carcinoma MHCC97-H cells with high metastasis potential and its relative mechanisms. J Asian Nat Prod Res. 2009;11(6):576-583.
34. Garmy-Sudini B, Avraamides CJ, Schmid MC, et al. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 2010;70(8):3042-3051.
35. Janik ME, Litynska A, Vereecken P. Cell migration - the role of integrin glycosylation. D. Biochim Biophys Acta. 2010;1800(6):545-555.
36. Kruegel J, Miosge N. Basement membrane components are key players in specialized extracellular matrices. Cell Mol Life Sci. 2010;67(17): 2879-2895.
37. Wiradjaja F, DiTommaso T, Smyth I. Basement membranes in development and disease. Birth Defects Res C Embryo Today. 2010;90(1):8-31.
38. Escaff S, Fernández JM, González LO, et al. Study of matrix metallopro-teinases and their inhibitors in prostate cancer. Br J Cancer. 2010;102(5): 922-929.